NEW YORK (TheStreet) -- Johnson & Johnson (JNJ) - Get Report stock is climbing by 1.08% to $97.44 in early-morning trading on Tuesday, after the medical device and pharmaceutical company reported its 2015 fourth quarter financial results before the market open.
The company posted adjusted earnings of $1.44 per share for the most recent quarter, up from $1.37 per share for the year-ago period.
Revenue declined by 2.4% to $17.81 billion, down from $18.25 billion for the 2014 fourth quarter. Sales were negatively impacted by the strong dollar.
Analysts surveyed by Thomson Reuters expected the company to post earnings of $1.42 a share on revenue of $17.88 billion for the quarter.
"Johnson & Johnson delivered strong underlying growth in 2015, driven by the performance of our pharmaceutical business and iconic consumer brands," CEO Alex Gorsky said in a statement.
Johnson & Johnson now expects 2016 full-year adjusted earnings to range between $6.43 and $6.58 per share, and for full-year sales to range between $70.8 billion and $71.5 billion.
Analysts surveyed by Thomson Reuters expect earnings of $6.38 per share on sales of $71.88 billion for the year.
Separately, TheStreet Ratings team rates the stock as a "buy" with a ratings score of A-.
Johnson & Johnson's strengths such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and expanding profit margins outweigh the fact that the company has had sub par growth in net income.
You can view the full analysis from the report here: JNJ
TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this article's author.